• Over the last few years experimental evidence for

  2022-06-13

  

  Over the last few years, experimental evidence for the involvement of Epac1 in cancer progression is beginning to emerge (Almahariq et al., 2015, Banerjee and Cheng, 2015, Parnell et al., 2015, Parnell et al., 2015, Schmidt et al., 2013). For example in melanoma cells, silencing of Epac1 attenuates

• Of what interest is the link between GSNOR and

  2022-06-13

  

  Of what interest is the link between GSNOR and NO in the plant response to Fe deficiency? On the one hand, NO acts as an important signal to help plants accommodate Fe deficiencies; on the other hand, surplus NO is indeed a harmful RNS that induces severe S-nitrosylation-related damage at a higher s

• Apart from the different assays

  2022-06-13

  

  Apart from the different assays used, biased agonism could also explain the inconsistent pharmacology of GPR55. Indeed, one study compared the effect of LPIs and Virodhamine in HEK293 smad inhibitor stably transfected with human GPR55. They found that the effect of both ligands on intracellular Ca2

• The GPR receptor is also emerging as an

  2022-06-13

  

  The GPR55 receptor is also emerging as an important therapeutic target. GPR55−/− mice possess no overt phenotype, but were protected in models of inflammatory and neuropathic pain (Staton et al., 2008). Staton et al. (2008) reported that no GPR55 mRNA could be detected by RT-PCR in the animals. Also

• GLP is an intestinal peptide hormone that

  2022-06-13

  

  GLP-1 is an intestinal peptide hormone that is released by the gut following ingestion of food, particularly BKT140 and fats. Following its release, GLP-1 stimulates pancreatic β-cells to secrete insulin (Hirasawa et al., 2005, Covington et al., 2006). Originally, GLP-1 acted in a similar manner to

• The importance of FXR FGF signaling in BA

  2022-06-13

  

  The importance of FXR-FGF15/19 signaling in BA homeostasis is illustrated by various BA malabsorption syndromes. Clinically, BA malabsorption causes diarrhea due to high BA concentrations in the colon that lead to secretion of water and electrolytes and stimulation of propulsive contractions [36]. P

• GnRH ant have been designed to obtain pharmacological compou

  2022-06-13

  

  GnRH-ant have been designed to obtain pharmacological compounds to block the pituitary–gonadal axis without the undesirable flare effect exerted by GnRH itself or by the GnRH-a (see Section 2.2). GnRH-ant competitively block the binding of GnRH to GnRHRs (Schally, 1999; Tan & Bukulmez, 2011); they p

• Ironically another series of studies examining the

  2022-06-13

  

  Ironically, another series of studies examining the role of EAATs in CNS injury and disease suggest that under some pathological conditions, the operation of the EAATs is not protective, but actually contributes to the excitotoxic process (Rossi et al., 2000). The transporters do so by serving as th

• In respect of clinical development Takeda

  2022-06-13

  

  In respect of clinical development Takeda has pioneered the field with the GPR40 agonist TAK-875 or fasiglifam (Figure 2A), which in phase-II studies decreased HbA1c as efficiently as sulfonylurea without signs of hypoglycemia [24]. This was obtained with surprisingly little effect on systemic insul

• br Experimental methods br Acknowledgments We thank all memb

  2022-06-13

  

  Experimental methods Acknowledgments We thank all members of the Hermanson lab, especially Ana Teixeira, Shirin Ilkhanizadeh and Karolina Wallenborg, for assistance and discussions, Peter Löw for anti-synaptotagmin antibody, and Lars Björklund, Ole Isacson, Christer Höög, Claes Wahlestedt and

• The expression of GLUT receptors throughout

  2022-06-13

  

  The expression of GLUT receptors throughout the body could be considered a potential source for off-target effects even for engineered glucose-conjugated nanomedicines, as there are at least 12 types of GLUT transporters in the body, including GLUT1 in erythrocytes and the blood-brain barrier, as we

• br Acknowledgements This work was supported by the National

  2022-06-13

  

  Acknowledgements This work was supported by the National Institutes of Health [grant number GM024417]. Introduction In mammals, glucose is the major energy substrate supporting conceptus development after DMAP formation [1,2]. While the equine morula uses similar amounts of pyruvate and gluc

• br GLP R expression in the

  2022-06-13

  

  GLP-1R expression in the vascular endothelium Immunohistochemistry studies utilizing GLP-1R antibodies that have now been demonstrated to be non-specific [46], initially identified GLP-1R protein expression in both mouse mesenteric artery SMCs and heart coronary SMCs [7]. However, evidence for VS

• Olanzapine has been reported to attenuate insulin secretion

  2022-06-13

  

  Olanzapine has been reported to attenuate insulin secretion, cause insulin resistance (Chintoh et al., 2008) and reduce whole body carbohydrate oxidation (Klingerman et al., 2014). However, a blunting of these effects in Gcgr−/− mice would not appear to explain the protection against olanzapine-indu

• br Introduction The glucagon receptor GCGR is a G protein

  2022-06-13

  

  Introduction The glucagon receptor (GCGR) is a G-protein-coupled receptor expressed mainly in the liver and kidney. Upon glucagon binding, it activates the stimulatory G protein (Gs) and increases cAMP level, subsequently transducing glucagon signaling involved in glucose, amino acids and lipid m

15911 records 410/1061 page Previous Next First page 上5页 406407408409410 下5页 Last page